Clinical Trial Update: TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) [Phase 1]

View source ↗

Summary

Phase 1 trial of IMA201-101 TCR-engineered T cells for solid tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• IMA201-101 (IMA201 TCR-engineered T cells)

Snippet

Sponsor: Immatics US, Inc. | Conditions: Solid Tumor, Cancer | Phase 1 | Status: COMPLETED